Clinical & Pharma

Infant Botulism Outbreak Linked to ByHeart Formula in 2025
Clinical & Pharma Infant Botulism Outbreak Linked to ByHeart Formula in 2025

In a startling development that has sent ripples through the public health community, a multistate outbreak of infant botulism has been traced to a specific brand of powdered infant formula, raising urgent concerns among parents and caregivers nationwide. The Centers for Disease Control and

Joan Brugge’s Breast Cancer Breakthrough Faces Funding Cuts
Clinical & Pharma Joan Brugge’s Breast Cancer Breakthrough Faces Funding Cuts

In a world where medical advancements hold the promise of transforming lives, the pioneering research of Joan Brugge, co-director of Harvard University’s Ludwig Center, stands out as a beacon of hope in the fight against breast cancer. Her innovative approach focuses on targeting and eliminating

Trump Secures Deal to Slash GLP-1 Drug Prices by 2026
Clinical & Pharma Trump Secures Deal to Slash GLP-1 Drug Prices by 2026

In a landmark development that could transform the affordability of critical medications for millions of Americans, the Trump administration has finalized a historic agreement with pharmaceutical powerhouses Eli Lilly and Novo Nordisk to significantly reduce the prices of GLP-1 drugs by 2026. These

Can Probabilistic Models Redefine Malaria Treatment Failure?
Clinical & Pharma Can Probabilistic Models Redefine Malaria Treatment Failure?

In the relentless fight against malaria, particularly the deadly Plasmodium falciparum strain, late treatment failure stands as a formidable barrier to global health progress, characterized by the reappearance of malaria parasites in the bloodstream after an initially successful drug response. This

How Do Drug Patents Raise Prices and Limit Innovation?
Clinical & Pharma How Do Drug Patents Raise Prices and Limit Innovation?

The pharmaceutical industry stands as a pillar of modern healthcare, tirelessly working to develop life-saving medications through rigorous research and development efforts that often span years and cost billions. Yet, the very system designed to protect and incentivize this innovation—the patent

Alarming Surge in Superbug CP-CRE Threatens US Hospitals
Clinical & Pharma Alarming Surge in Superbug CP-CRE Threatens US Hospitals

In a chilling development for healthcare systems across the United States, a dramatic increase in multidrug-resistant bacteria known as carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) has emerged as a formidable challenge in hospitals, often dubbed a "superbug" due to its

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later